301 related articles for article (PubMed ID: 9620913)
1. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin.
Kudoh S; Azuma A; Yamamoto M; Izumi T; Ando M
Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1829-32. PubMed ID: 9620913
[TBL] [Abstract][Full Text] [Related]
2. [Diffuse panbronchiolitis: DPB].
Azuma A; Kudoh S
Nihon Rinsho; 1999 Sep; 57(9):2123-7. PubMed ID: 10497417
[TBL] [Abstract][Full Text] [Related]
3. Diffuse panbronchiolitis, the first case reports in Thailand.
Chantarotorn S; Palwatwichai A; Vattanathum A; Tantamacharik D
J Med Assoc Thai; 1999 Aug; 82(8):833-8. PubMed ID: 10511794
[TBL] [Abstract][Full Text] [Related]
4. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis.
Nagai H; Shishido H; Yoneda R; Yamaguchi E; Tamura A; Kurashima A
Respiration; 1991; 58(3-4):145-9. PubMed ID: 1745845
[TBL] [Abstract][Full Text] [Related]
5. [Clinical effects of low-dose and long-term erythromycin in diffuse panbronchiolitis with chronic respiratory failure].
Ohno S; Sugiyama Y; Kitamura S
Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Oct; 31(10):1251-6. PubMed ID: 8271657
[TBL] [Abstract][Full Text] [Related]
6. Diffuse panbronchiolitis-The response and recurrence after erythromycin therapy.
Chuang MC; Chou YT; Lin YC; Hsieh MJ; Tsai YH
J Formos Med Assoc; 2016 Oct; 115(10):876-882. PubMed ID: 26705139
[TBL] [Abstract][Full Text] [Related]
7. Elevation of tumor-associated carbohydrate antigens in patients with diffuse panbronchiolitis.
Mukae H; Hirota M; Kohno S; Komori K; Fukushima K; Hiratani K; Kadota J; Hara K
Am Rev Respir Dis; 1993 Sep; 148(3):744-51. PubMed ID: 8103656
[TBL] [Abstract][Full Text] [Related]
8. [Long-term therapeutic effects of erythromycin and newquinolone antibacterial agents on diffuse panbronchiolitis].
Yamamoto M; Kondo A; Tamura M; Izumi T; Ina Y; Noda M
Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Oct; 28(10):1305-13. PubMed ID: 2273658
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of peripheral lymphocyte subsets and changes due to erythromycin therapy in patients with diffuse panbronchiolitis].
Sugiyama Y; Sugama Y; Takeuchi K; Kudoh S; Kitamura S
Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Dec; 28(12):1574-80. PubMed ID: 2077202
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of cases allowed to cease erythromycin therapy for diffuse panbronchiolitis--comparative study between patients with cessation of the therapy and patients continuing the therapy].
Shirai R; Abe K; Yoshinaga M; Ishimatsu Y; Matsubara Y; Kawakami K; Iida K; Fujii T; Kawamoto S; Kaseda M; Kadota J; Kohno S
Kansenshogaku Zasshi; 1997 Nov; 71(11):1155-61. PubMed ID: 9455056
[TBL] [Abstract][Full Text] [Related]
11. [Diffuse panbronchiolitis in a child: case report and literature review].
Zhao SY; Peng Y; Zhou CJ; Jiao AX; Jiang ZF
Zhonghua Er Ke Za Zhi; 2007 Jul; 45(7):504-7. PubMed ID: 17953806
[TBL] [Abstract][Full Text] [Related]
12. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis.
Kadota J; Sakito O; Kohno S; Sawa H; Mukae H; Oda H; Kawakami K; Fukushima K; Hiratani K; Hara K
Am Rev Respir Dis; 1993 Jan; 147(1):153-9. PubMed ID: 8420410
[TBL] [Abstract][Full Text] [Related]
13. Superoxide dismutase in alveolar macrophages from patients with diffuse panbronchiolitis.
Morikawa T; Kadota JI; Kohno S; Kondo T
Respiration; 2000; 67(5):546-51. PubMed ID: 11070461
[TBL] [Abstract][Full Text] [Related]
14. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients.
Ichikawa Y; Ninomiya H; Koga H; Tanaka M; Kinoshita M; Tokunaga N; Yano T; Oizumi K
Am Rev Respir Dis; 1992 Jul; 146(1):196-203. PubMed ID: 1626803
[TBL] [Abstract][Full Text] [Related]
15. The effect of long-term treatment with erythromycin on Th1 and Th2 cytokines in diffuse panbronchiolitis.
Park SJ; Lee YC; Rhee YK; Lee HB
Biochem Biophys Res Commun; 2004 Nov; 324(1):114-7. PubMed ID: 15464990
[TBL] [Abstract][Full Text] [Related]
16. [Application of macrolides to diffuse panbronchiolitis].
Kudoh S
Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():554-8. PubMed ID: 17455680
[No Abstract] [Full Text] [Related]
17. Idiopathic bronchiolitis mimicking diffuse panbronchiolitis.
Poletti V; Chilosi M; Trisolini R; Cancellieri A; Zompatori M; Lazzari Agli L; Boaron M; Schulte W; Theegarten D; Guzman J; Costabel U
Sarcoidosis Vasc Diffuse Lung Dis; 2003 Mar; 20(1):62-8. PubMed ID: 12737282
[TBL] [Abstract][Full Text] [Related]
18. Azithromycin treats diffuse panbronchiolitis by targeting T cells via inhibition of mTOR pathway.
Weng D; Wu Q; Chen XQ; Du YK; Chen T; Li H; Tang DL; Li QH; Zhang Y; Lu LQ; Zhou NY; Song JC; Wang C; Li HP
Biomed Pharmacother; 2019 Feb; 110():440-448. PubMed ID: 30530046
[TBL] [Abstract][Full Text] [Related]
19. Diffuse panbronchiolitis and rheumatoid arthritis-associated bronchiolar disease: similarities and differences.
Hayakawa H; Sato A; Imokawa S; Todate A; Chida K; Suzuki K; Iwata M
Intern Med; 1998 Jun; 37(6):504-8. PubMed ID: 9678682
[TBL] [Abstract][Full Text] [Related]
20. [A clinical study of the long-term therapeutic effects of low-dose erythromycin in diffuse panbronchiolitis--with special reference to changes in tumor-associated carbohydrate antigens in serum].
Mukae H; Komori K; Morikawa N; Sakito O; Oda H; Senju R; Fukushima K; Hiratani K; Kadota J; Hara K
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 May; 30(5):802-7. PubMed ID: 1352834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
